PHOENIX, Nov. 6, 2017 /PRNewswire/ -- Researchers from the Banner Alzheimer's Institute (BAI), Novartis, and Amgen today
"This expanded collaboration builds upon the API Generation Study 1 which launched last year, and is another step in our effort to take clinical trials to a critical new stage," said Pierre N. Tariot, MD, co-director of API and director of BAI, a division of Banner Health, one of the largest nonprofit healthcare systems in the United States. "This approach continues to shift the Alzheimer's research paradigm from reversing disease damage to attacking its root cause before symptoms surface. It is our hope that by targeting people earlier, we will have a better chance of delaying or preventing the onset of the disease."
The five-year Generation Study 2 will involve more than 2,000 cognitively healthy volunteers, ages 60 to 75, who are at high risk of developing symptoms of Alzheimer's because of their age and because they carry either one or two copies of the e4 type of the apolipoprotein E (APOE) gene, the major genetic risk factor for late-onset Alzheimer's disease. Eligible participants will be randomized to receive one of two doses of the investigational anti-amyloid compound CNP520 (15 mg or 50 mg), co-developed by Novartis Pharmaceutical Corporation and biotechnology company Amgen, or a placebo. The Generation Study 2 began enrolling participants in August and will be conducted at more than 180 sites in more than 20 countries around the world.
Both studies are part of a research effort known as the API Generation Program. The first trial, Generation Study 1, is examining whether two investigational anti-amyloid compounds – CAD106, an active immunotherapy, and CNP520 – can prevent or delay the emergence of symptoms of Alzheimer's among higher-risk cognitively healthy older adults who have two copies of the e4 type of the APOE gene, one from each parent.
Roughly one in four people carry a single copy of the e4 type of the APOE gene, but only about two percent of the world's population carries two copies. The Generation Study 2 will include volunteers with two copies, as well as those with one copy who already show evidence of elevated brain amyloid. Both these groups are at particularly elevated risk of developing symptoms of Alzheimer's by age 85. The API Generation Program is the first to incorporate both genetic testing and counseling in addition to amyloid disclosure education into the study screening process. For both studies, prospective participants referred to the trial will be required to learn their APOE test results. Only those who learn they have one or two copies may be eligible to participate in the study. In Generation Study 2, testing will also determine the participant's amyloid status, which will be disclosed by qualified medical personnel. Genetic counseling will be provided in person or by phone.
Participants will be recruited via multiple venues, including, in the U.S., the Alzheimer's Prevention Registry's GeneMatch program (www.endALZnow.org/GeneMatch). GeneMatch is a first-of-its-kind program designed to identify a large group of people interested in volunteering for Alzheimer's research studies, based in part on their APOE genetic information.
"An estimated 80 percent of studies fail to meet their recruitment goals, which can delay important research efforts," said Jessica Langbaum, PhD principal scientist at BAI and associate director of the API. "The GeneMatch program is helping us to identify eligible volunteers for the Generation Study 2 at an accelerated rate, which will be vital to the study's success."
Formed in 2011, API is championed by BAI and supported by the National Institutes of Health to accelerate Alzheimer's prevention research by evaluating the most promising therapies in cognitively normal people who – based on age and genetic background – are at the highest risk of developing Alzheimer's disease symptoms.
"We are excited about the opportunity to work with our Novartis and Amgen colleagues to further accelerate the evaluation of promising prevention therapies, so it may be possible to find ones that work for the widest range of people at risk for developing Alzheimer's," said Eric M. Reiman, MD, API co-director and BAI's executive director. "Once again, we are also excited about the opportunity that this public-private partnership provides to advance Alzheimer's prevention research in ways that will have the maximum public benefit."
View original content:http://www.prnewswire.com/news-releases/banner-alzheimers-institute-novartis-and-amgen-expand-collaboration-in-pioneering-alzheimers-prevention-program-300550036.html
SOURCE Banner Alzheimer's Institute
Subscribe to our Free Newsletters!
Exfoliative dermatitis or erythroderma is a skin condition where the skin becomes reddened and ...
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...View All